APA (7th ed.) Citation

Papachristofilou, A., Sebastian, M., & Bischoff, H. (2019). Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. BioMed Central. https://doi.org/10.1186/s40425-019-0520-5

Chicago Style (17th ed.) Citation

Papachristofilou, Alexandros, Martin Sebastian, and Helge Bischoff. Phase Ib Evaluation of a Self-adjuvanted Protamine Formulated MRNA-based Active Cancer Immunotherapy, BI1361849 (CV9202), Combined with Local Radiation Treatment in Patients with Stage IV Non-small Cell Lung Cancer. London: BioMed Central, 2019. https://doi.org/10.1186/s40425-019-0520-5.

MLA (9th ed.) Citation

Papachristofilou, Alexandros, et al. Phase Ib Evaluation of a Self-adjuvanted Protamine Formulated MRNA-based Active Cancer Immunotherapy, BI1361849 (CV9202), Combined with Local Radiation Treatment in Patients with Stage IV Non-small Cell Lung Cancer. BioMed Central, 2019. https://doi.org/10.1186/s40425-019-0520-5.